A Phase I Dose Escalation Study of Intrathecal DepoFoam Encapsulated Cytarabine (DTC 101) in Pediatric Patients With Advanced Meningeal Malignancies
Sponsor study identifier
Secondary identifiers
interventional
15
2 countries
6
Study Start
February 1997
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
Not reported
Date not reportedRATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of liposomal cytarabine in treating young patients who have recurrent or refractory meningeal leukemia, lymphoma, or solid tumors.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 1997
Date type not reportedThis date has not been verified as actual or estimated.
November 1, 1999
Actual (reported)February 6, 2004
Actual (reported)Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.
Formulated product
liposomal cytarabine
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
View registry recordChildren's Hospital Los Angeles
Los Angeles, California, 90027-0700, United States
Stanford University Medical Center
Stanford, California, 94305-5408, United States
University of Texas Southwestern Medical Center at Dallas
Dallas, Texas, 75235-8897, United States
Texas Children's Cancer Center
Houston, Texas, 77030-2399, United States
Children's Hospital and Regional Medical Center - Seattle
Seattle, Washington, 98105, United States
Alberta Children's Hospital
Calgary, Alberta, T2T 5C7, Canada
John E. Gait, MD
Pacira Pharmaceuticals, Inc
First Submitted
November 1, 1999
First Posted
February 6, 2004
Study Start
February 1997
Date type not reportedThis date has not been verified as actual or estimated.
Last Updated
March 23, 2010
Record last verified: 2002-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved:
Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.